CD19 and classic Hodgkin lymphoma: In 2018, Svoboda et al. reported the transient responses of CD19-targeted mRNA engineered T cells (CD19 CAR T) in patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL).